|
GB9714249D0
(en)
|
1997-07-08 |
1997-09-10 |
Angiogene Pharm Ltd |
Vascular damaging agents
|
|
SE9903544D0
(sv)
|
1999-10-01 |
1999-10-01 |
Astra Pharma Prod |
Novel compounds
|
|
GB2359551A
(en)
|
2000-02-23 |
2001-08-29 |
Astrazeneca Uk Ltd |
Pharmaceutically active pyrimidine derivatives
|
|
AR028948A1
(es)
|
2000-06-20 |
2003-05-28 |
Astrazeneca Ab |
Compuestos novedosos
|
|
JP2004502766A
(ja)
*
|
2000-07-07 |
2004-01-29 |
アンギオジェン・ファーマシューティカルズ・リミテッド |
血管損傷剤としてのコルヒノール誘導体
|
|
US6720323B2
(en)
|
2000-07-07 |
2004-04-13 |
Angiogene Pharmaceuticals Limited |
Colchinol derivatives as angiogenesis inhibitors
|
|
SE0003828D0
(sv)
|
2000-10-20 |
2000-10-20 |
Astrazeneca Ab |
Novel compounds
|
|
JP2005507912A
(ja)
|
2001-10-26 |
2005-03-24 |
オキシジーン， インコーポレイテッド |
改良型血管標的化剤としての官能化スチルベン誘導体
|
|
KR101093345B1
(ko)
|
2002-02-01 |
2011-12-14 |
아스트라제네카 아베 |
퀴나졸린 화합물
|
|
GB0217431D0
(en)
|
2002-07-27 |
2002-09-04 |
Astrazeneca Ab |
Novel compounds
|
|
JP4694963B2
(ja)
|
2002-08-24 |
2011-06-08 |
アストラゼネカ・アクチエボラーグ |
ケモカインレセプター活性のモジュレーターとしてのピリミジン誘導体
|
|
GB0221828D0
(en)
|
2002-09-20 |
2002-10-30 |
Astrazeneca Ab |
Novel compound
|
|
RU2357971C2
(ru)
|
2002-12-24 |
2009-06-10 |
Астразенека Аб |
Производные фосфонооксихиназолина и их фармацевтическое применение
|
|
WO2004078126A2
(en)
|
2003-02-28 |
2004-09-16 |
Oxigene, Inc. |
Compositions and methods with enhanced therapeutic activity
|
|
SE0301010D0
(sv)
|
2003-04-07 |
2003-04-07 |
Astrazeneca Ab |
Novel compounds
|
|
SE0301569D0
(sv)
|
2003-05-27 |
2003-05-27 |
Astrazeneca Ab |
Novel compounds
|
|
UA84175C2
(ru)
|
2003-11-19 |
2008-09-25 |
Аррей Байофарма Инк. |
Гетероциклические ингибиторы мэк и их применение
|
|
GB0328243D0
(en)
|
2003-12-05 |
2004-01-07 |
Astrazeneca Ab |
Methods
|
|
GB0329771D0
(en)
*
|
2003-12-23 |
2004-01-28 |
Angiogene Pharm Ltd |
Chemical processes & intermediates
|
|
DE602004031777D1
(en)
|
2004-01-05 |
2011-04-21 |
Astrazeneca Ab |
Thiophenderivate als chk-1-inhibitoren
|
|
SE0401657D0
(sv)
|
2004-06-24 |
2004-06-24 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0415320D0
(en)
|
2004-07-08 |
2004-08-11 |
Astrazeneca Ab |
Novel compounds
|
|
CN102796081B
(zh)
|
2004-08-28 |
2015-04-22 |
阿斯利康(瑞典)有限公司 |
作为趋化因子受体调节剂的嘧啶磺酰胺衍生物
|
|
NZ556029A
(en)
|
2004-12-21 |
2010-04-30 |
Astrazeneca Ab |
Antibodies directed to angiopoietin-2 and uses thereof
|
|
GB0428100D0
(en)
*
|
2004-12-23 |
2005-01-26 |
Astrazeneca Ab |
Chemical processes & intermediates
|
|
ATE530545T1
(de)
|
2005-02-04 |
2011-11-15 |
Astrazeneca Ab |
Als kinaseinhibitoren geeignete pyrazolylaminopyridinderivate
|
|
ES2397418T3
(es)
|
2005-07-21 |
2013-03-06 |
Astrazeneca Ab |
Derivados de piperidina
|
|
TW200738634A
(en)
|
2005-08-02 |
2007-10-16 |
Astrazeneca Ab |
New salt
|
|
TW200738658A
(en)
|
2005-08-09 |
2007-10-16 |
Astrazeneca Ab |
Novel compounds
|
|
WO2007034916A1
(ja)
|
2005-09-22 |
2007-03-29 |
Dainippon Sumitomo Pharma Co., Ltd. |
新規アデニン化合物
|
|
US20090118263A1
(en)
|
2005-09-22 |
2009-05-07 |
Dainippon Sumitomo Pharma Co., Ltd. |
Novel Adenine Compound
|
|
JPWO2007034917A1
(ja)
|
2005-09-22 |
2009-03-26 |
大日本住友製薬株式会社 |
新規なアデニン化合物
|
|
US20080269240A1
(en)
|
2005-09-22 |
2008-10-30 |
Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan |
Novel Adenine Compound
|
|
US20090192153A1
(en)
|
2005-09-22 |
2009-07-30 |
Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan |
Novel adenine compound
|
|
EP1937632A1
(en)
|
2005-10-06 |
2008-07-02 |
Astra Zeneca AB |
Novel compounds
|
|
TW200800963A
(en)
|
2005-10-28 |
2008-01-01 |
Astrazeneca Ab |
Chemical compounds
|
|
BRPI0618668B1
(pt)
|
2005-11-15 |
2021-09-21 |
Array Biopharma Inc |
Compostos inibidores dos receptores de tirosina quinase do tipo i, composições compreendendo tais compostos, e seus usos
|
|
TW200730512A
(en)
|
2005-12-12 |
2007-08-16 |
Astrazeneca Ab |
Novel compounds
|
|
PL1979001T3
(pl)
|
2005-12-13 |
2012-09-28 |
Medimmune Ltd |
Białka wiążące specyficzne dla insulinopodobnych czynników wzrostu i ich zastosowania
|
|
EP2305640A3
(en)
|
2005-12-15 |
2011-07-20 |
AstraZeneca AB |
Substituted diphenyl-ethers, -amines, -sulfides and -methanes for the treatment of respiratory diseases
|
|
TW200813091A
(en)
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
|
JP2009538289A
(ja)
|
2006-05-26 |
2009-11-05 |
アストラゼネカ・アクチエボラーグ |
ビアリールまたはヘテロアリール置換インドール
|
|
CL2007002225A1
(es)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
|
|
DE102006037478A1
(de)
|
2006-08-10 |
2008-02-14 |
Merck Patent Gmbh |
2-(Heterocyclylbenzyl)-pyridazinonderivate
|
|
WO2008023161A1
(en)
*
|
2006-08-23 |
2008-02-28 |
Kudos Pharmaceuticals Limited |
2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
|
|
TW200825084A
(en)
|
2006-11-14 |
2008-06-16 |
Astrazeneca Ab |
New compounds 521
|
|
TW200831528A
(en)
|
2006-11-30 |
2008-08-01 |
Astrazeneca Ab |
Compounds
|
|
JP4604129B2
(ja)
|
2006-12-19 |
2010-12-22 |
アストラゼネカ・アクチエボラーグ |
ムスカリン受容体アンタゴニストとしてのキヌクリジノール誘導体
|
|
CL2008000191A1
(es)
|
2007-01-25 |
2008-08-22 |
Astrazeneca Ab |
Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer.
|
|
US8044056B2
(en)
|
2007-03-20 |
2011-10-25 |
Dainippon Sumitomo Pharma Co., Ltd. |
Adenine compound
|
|
PE20081887A1
(es)
|
2007-03-20 |
2009-01-16 |
Dainippon Sumitomo Pharma Co |
Nuevo compuesto de adenina
|
|
UA99459C2
(en)
|
2007-05-04 |
2012-08-27 |
Астразенека Аб |
9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
|
|
DE102007025718A1
(de)
|
2007-06-01 |
2008-12-04 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
DE102007025717A1
(de)
|
2007-06-01 |
2008-12-11 |
Merck Patent Gmbh |
Arylether-pyridazinonderivate
|
|
DE102007026341A1
(de)
|
2007-06-06 |
2008-12-11 |
Merck Patent Gmbh |
Benzoxazolonderivate
|
|
UA100983C2
(ru)
|
2007-07-05 |
2013-02-25 |
Астразенека Аб |
Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
|
|
DE102007032507A1
(de)
|
2007-07-12 |
2009-04-02 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
DE102007038957A1
(de)
|
2007-08-17 |
2009-02-19 |
Merck Patent Gmbh |
6-Thioxo-pyridazinderivate
|
|
DE102007041115A1
(de)
|
2007-08-30 |
2009-03-05 |
Merck Patent Gmbh |
Thiadiazinonderivate
|
|
CN101883778A
(zh)
|
2007-10-04 |
2010-11-10 |
阿斯利康(瑞典)有限公司 |
具有糖皮质激素活性的甾类[3，2-c]吡唑化合物
|
|
TWI453021B
(zh)
|
2007-10-11 |
2014-09-21 |
Astrazeneca Ab |
新穎蛋白質激酶ｂ抑制劑
|
|
DE102007061963A1
(de)
|
2007-12-21 |
2009-06-25 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
AU2008339576B2
(en)
|
2007-12-21 |
2014-05-22 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4Ralpha)
|
|
US8092804B2
(en)
|
2007-12-21 |
2012-01-10 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
|
|
EA018711B1
(ru)
|
2008-02-06 |
2013-10-30 |
Астразенека Аб |
Производные диазаспиро[5.5]ундекана в качестве антагонистов мускариновых рецепторов и агонистов бета-адренорецепторов для применения в лечении легочных расстройств
|
|
ES2401550T3
(es)
|
2008-02-28 |
2013-04-22 |
Merck Patent Gmbh |
Inhibidores de proteína cinasa y uso de los mismos
|
|
DE102008019907A1
(de)
|
2008-04-21 |
2009-10-22 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
BRPI0912103A2
(pt)
|
2008-05-27 |
2021-04-20 |
Astrazeneca Ab |
derivados de fenoxipiridinilamida e seu uso no tratamento de estados de doenças mediados por pde4
|
|
DE102008025750A1
(de)
|
2008-05-29 |
2009-12-03 |
Merck Patent Gmbh |
Dihydropyrazolderivate
|
|
DE102008028905A1
(de)
|
2008-06-18 |
2009-12-24 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
|
|
DE102008029734A1
(de)
|
2008-06-23 |
2009-12-24 |
Merck Patent Gmbh |
Thiazolyl-piperidinderivate
|
|
UY31952A
(es)
|
2008-07-02 |
2010-01-29 |
Astrazeneca Ab |
5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
|
|
DE102008037790A1
(de)
|
2008-08-14 |
2010-02-18 |
Merck Patent Gmbh |
Bicyclische Triazolderivate
|
|
DE102008038221A1
(de)
|
2008-08-18 |
2010-02-25 |
Merck Patent Gmbh |
7-Azaindolderivate
|
|
JP5778577B2
(ja)
|
2008-09-19 |
2015-09-16 |
メディミューン，エルエルシー |
Ｄｌｌ４に対する抗体およびその使用
|
|
DE102008052943A1
(de)
|
2008-10-23 |
2010-04-29 |
Merck Patent Gmbh |
Azaindolderivate
|
|
WO2010067102A1
(en)
|
2008-12-09 |
2010-06-17 |
Astrazeneca Ab |
Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders
|
|
CN102292097B
(zh)
|
2008-12-11 |
2015-05-27 |
艾克赛特药品有限公司 |
染料木黄酮的晶型
|
|
US7863325B2
(en)
|
2008-12-11 |
2011-01-04 |
Axcentua Pharmaceuticals Ab |
Crystalline genistein sodium salt dihydrate
|
|
US20100152197A1
(en)
|
2008-12-15 |
2010-06-17 |
Astrazeneca Ab |
(4-tert-butylpiperazin-2-yl)(piperazin-1-yl)methanone-n-carboxamide derivatives
|
|
CA2745071C
(en)
|
2008-12-17 |
2018-08-28 |
Yufang Xiao |
C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof
|
|
EP2367822B1
(en)
|
2008-12-18 |
2016-10-05 |
Merck Patent GmbH |
Tricyclic azaindoles
|
|
DE102008063667A1
(de)
|
2008-12-18 |
2010-07-01 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate
|
|
TW201028410A
(en)
|
2008-12-22 |
2010-08-01 |
Astrazeneca Ab |
Chemical compounds 610
|
|
CA2748158A1
(en)
|
2008-12-23 |
2010-07-01 |
Astrazeneca Ab |
Targeted binding agents directed to .alpha.5.beta.1 and uses thereof
|
|
DE102008062826A1
(de)
|
2008-12-23 |
2010-07-01 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
DE102008062825A1
(de)
|
2008-12-23 |
2010-06-24 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo [4,3-b]pyridazin-derivate
|
|
DE102009003975A1
(de)
|
2009-01-07 |
2010-07-08 |
Merck Patent Gmbh |
Benzothiazolonderivate
|
|
DE102009003954A1
(de)
|
2009-01-07 |
2010-07-08 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
DE102009004061A1
(de)
|
2009-01-08 |
2010-07-15 |
Merck Patent Gmbh |
Pyridazinonderivate
|
|
WO2010089580A1
(en)
|
2009-02-06 |
2010-08-12 |
Astrazeneca Ab |
Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
|
|
WO2010092371A1
(en)
|
2009-02-10 |
2010-08-19 |
Astrazeneca Ab |
Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer
|
|
GB0905127D0
(en)
|
2009-03-25 |
2009-05-06 |
Pharminox Ltd |
Novel prodrugs
|
|
UY32520A
(es)
|
2009-04-03 |
2010-10-29 |
Astrazeneca Ab |
Compuestos que tienen actividad agonista del receptor de glucocorticoesteroides
|
|
US8389580B2
(en)
|
2009-06-02 |
2013-03-05 |
Duke University |
Arylcyclopropylamines and methods of use
|
|
US20100317593A1
(en)
|
2009-06-12 |
2010-12-16 |
Astrazeneca Ab |
2,3-dihydro-1h-indene compounds
|
|
GB0913342D0
(en)
|
2009-07-31 |
2009-09-16 |
Astrazeneca Ab |
Compounds - 801
|
|
DE102009043260A1
(de)
|
2009-09-28 |
2011-04-28 |
Merck Patent Gmbh |
Pyridinyl-imidazolonderivate
|
|
KR20120099639A
(ko)
|
2009-10-02 |
2012-09-11 |
아스트라제네카 아베 |
호중구 엘라스타제의 억제제로서 사용되는 2-피리돈 화합물
|
|
DE102009049679A1
(de)
|
2009-10-19 |
2011-04-21 |
Merck Patent Gmbh |
Pyrazolopyrimidinderivate
|
|
WO2011048409A1
(en)
|
2009-10-20 |
2011-04-28 |
Astrazeneca Ab |
Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
|
|
US8399460B2
(en)
|
2009-10-27 |
2013-03-19 |
Astrazeneca Ab |
Chromenone derivatives
|
|
CA2777746C
(en)
|
2009-11-18 |
2019-05-14 |
Astrazeneca Ab |
Benzoimidazole compounds and uses thereof
|
|
RS60033B1
(sr)
|
2009-11-24 |
2020-04-30 |
Medimmune Ltd |
Ciljano vezujući agensi usmereni na b7-h1
|
|
EP2507237A1
(en)
|
2009-12-03 |
2012-10-10 |
Dainippon Sumitomo Pharma Co., Ltd. |
Imidazoquinolines which act via toll - like receptors (tlr)
|
|
DE102009058280A1
(de)
|
2009-12-14 |
2011-06-16 |
Merck Patent Gmbh |
Thiazolderivate
|
|
ES2438509T3
(es)
|
2009-12-14 |
2014-01-17 |
Merck Patent Gmbh |
Inhibidores de la esfingosina quinasa
|
|
CA2784647A1
(en)
|
2009-12-17 |
2011-07-14 |
Merck Patent Gmbh |
Inhibitors of sphingosine kinase
|
|
AU2011206864B2
(en)
|
2010-01-15 |
2013-12-19 |
Suzhou Neupharma Co., Ltd. |
Certain chemical entities, compositions, and methods
|
|
US8198285B2
(en)
|
2010-01-19 |
2012-06-12 |
Astrazeneca Ab |
Pyrazine derivatives
|
|
WO2011095807A1
(en)
|
2010-02-07 |
2011-08-11 |
Astrazeneca Ab |
Combinations of mek and hh inhibitors
|
|
WO2011114148A1
(en)
|
2010-03-17 |
2011-09-22 |
Astrazeneca Ab |
4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists
|
|
US20130059916A1
(en)
|
2010-05-26 |
2013-03-07 |
Stephane Rocchi |
Biguanide compounds and its use for treating cancer
|
|
WO2011154677A1
(en)
|
2010-06-09 |
2011-12-15 |
Astrazeneca Ab |
Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760
|
|
SA111320519B1
(ar)
|
2010-06-11 |
2014-07-02 |
Astrazeneca Ab |
مركبات بيريميدينيل للاستخدام كمثبطات atr
|
|
GB201009801D0
(en)
|
2010-06-11 |
2010-07-21 |
Astrazeneca Ab |
Compounds 950
|
|
UY33539A
(es)
|
2010-08-02 |
2012-02-29 |
Astrazeneca Ab |
Compuestos químicos alk
|
|
TWI535712B
(zh)
|
2010-08-06 |
2016-06-01 |
阿斯特捷利康公司 |
化合物
|
|
DE102010034699A1
(de)
|
2010-08-18 |
2012-02-23 |
Merck Patent Gmbh |
Pyrimidinderivate
|
|
US9018197B2
(en)
|
2010-08-28 |
2015-04-28 |
Suzhou Neupharma Co. Ltd. |
Tetradecahydro-1H-cyclopenta[a]phenanthrene compounds, compositions, and related methods of use
|
|
GB201016442D0
(en)
|
2010-09-30 |
2010-11-17 |
Pharminox Ltd |
Novel acridine derivatives
|
|
DE102010048800A1
(de)
|
2010-10-20 |
2012-05-10 |
Merck Patent Gmbh |
Chinoxalinderivate
|
|
DE102010049595A1
(de)
|
2010-10-26 |
2012-04-26 |
Merck Patent Gmbh |
Chinazolinderivate
|
|
WO2012066336A1
(en)
|
2010-11-19 |
2012-05-24 |
Astrazeneca Ab |
Benzylamine compounds as toll -like receptor 7 agonists
|
|
WO2012067269A1
(en)
|
2010-11-19 |
2012-05-24 |
Dainippon Sumitomo Pharma Co., Ltd. |
Aminoalkoxyphenyl compounds and their use in the treatment of disease
|
|
WO2012066335A1
(en)
|
2010-11-19 |
2012-05-24 |
Astrazeneca Ab |
Phenol compounds als toll -like receptor 7 agonists
|
|
EP2640716A1
(en)
|
2010-11-19 |
2013-09-25 |
Dainippon Sumitomo Pharma Co., Ltd. |
Cyclic amide compounds and their use in the treatment of disease
|
|
CN103370317B
(zh)
|
2010-12-16 |
2015-10-07 |
阿斯利康(瑞典)有限公司 |
可用于治疗的咪唑并[4,5-c]喹啉-1-基衍生物
|
|
JP5978226B2
(ja)
|
2010-12-17 |
2016-08-24 |
大日本住友製薬株式会社 |
プリン誘導体
|
|
JP2014508511A
(ja)
|
2010-12-20 |
2014-04-10 |
メドイミューン・リミテッド |
抗ｉｌ−１８抗体およびそれらの使用
|
|
EP2670763B1
(en)
|
2011-02-02 |
2018-08-01 |
Suzhou Neupharma Co., Ltd |
Certain chemical entities, compositions, and methods
|
|
US20130324532A1
(en)
|
2011-02-17 |
2013-12-05 |
Cancer Therapeutics Crc Pty Limited |
Fak inhibitors
|
|
ES2724525T3
(es)
|
2011-02-17 |
2019-09-11 |
Cancer Therapeutics Crc Pty Ltd |
Inhibidores selectivos de FAK
|
|
GB201104267D0
(en)
|
2011-03-14 |
2011-04-27 |
Cancer Rec Tech Ltd |
Pyrrolopyridineamino derivatives
|
|
UY34013A
(es)
|
2011-04-13 |
2012-11-30 |
Astrazeneca Ab |
?compuestos de cromenona con actividad anti-tumoral?.
|
|
WO2012175991A1
(en)
|
2011-06-24 |
2012-12-27 |
Pharminox Limited |
Fused pentacyclic anti - proliferative compounds
|
|
US20140227293A1
(en)
|
2011-06-30 |
2014-08-14 |
Trustees Of Boston University |
Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
|
|
AU2012282316B2
(en)
|
2011-07-12 |
2016-07-14 |
Astrazeneca Ab |
N- (6- ( (2R,3S) -3,4-Dihydroxybutan-2-yloxy) -2- (4 - fluorobenzylthio) pyrimidin- 4 - yl) -3- methylazetidine- 1 - sulfonamide as chemokine receptor modulator
|
|
LT3333161T
(lt)
|
2011-07-27 |
2020-05-11 |
Astrazeneca Ab |
2-(2,4,5-pakeistieji-anilino)pirimidino dariniai kaip egfr moduliatoriai, naudingi vėžio gydymui
|
|
CN103841828B
(zh)
|
2011-07-29 |
2016-01-13 |
美迪诺亚公司 |
德尼布林二盐酸盐
|
|
DE102011111400A1
(de)
|
2011-08-23 |
2013-02-28 |
Merck Patent Gmbh |
Bicyclische heteroaromatische Verbindungen
|
|
WO2013032951A1
(en)
|
2011-08-26 |
2013-03-07 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
|
WO2013033250A1
(en)
|
2011-09-01 |
2013-03-07 |
Xiangping Qian |
Certain chemical entities, compositions, and methods
|
|
AU2012308238B2
(en)
|
2011-09-14 |
2017-05-25 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
|
EP2757885B1
(en)
|
2011-09-21 |
2017-03-15 |
Neupharma, Inc. |
Certain chemical entites, compositions, and methods
|
|
WO2013045955A1
(en)
|
2011-09-29 |
2013-04-04 |
The University Of Liverpool |
Prevention and/or treatment of cancer and/or cancer metastasis
|
|
US9249111B2
(en)
|
2011-09-30 |
2016-02-02 |
Neupharma, Inc. |
Substituted quinoxalines as B-RAF kinase inhibitors
|
|
US20130178520A1
(en)
|
2011-12-23 |
2013-07-11 |
Duke University |
Methods of treatment using arylcyclopropylamine compounds
|
|
US9670180B2
(en)
|
2012-01-25 |
2017-06-06 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
|
CN104066734B
(zh)
|
2012-01-28 |
2017-03-29 |
默克专利股份公司 |
三唑并[4,5‑d]嘧啶衍生物
|
|
SI2812337T1
(sl)
|
2012-02-09 |
2017-01-31 |
Merck Patent Gmbh |
Furo (3,2-b) in tieno (3,2-b) piridinski derivati kot zaviralci tbk1 in ikk
|
|
EP2812323B1
(en)
|
2012-02-09 |
2016-04-06 |
Merck Patent GmbH |
Tetrahydro-quinazolinone derivatives as tank and parp inhibitors
|
|
ES2606638T3
(es)
|
2012-02-21 |
2017-03-24 |
Merck Patent Gmbh |
Derivados de furopiridina
|
|
JP6479476B2
(ja)
|
2012-02-21 |
2019-03-06 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ |
ＳｙｋチロシンキナーゼインヒビターおよびＧＣＮ２セリンキナーゼインヒビターとしての８−置換２−アミノー［１，２，４］トリアゾロ［１，５−Ａ］ピラジン類
|
|
ES2552518T3
(es)
|
2012-02-21 |
2015-11-30 |
Merck Patent Gmbh |
Derivados cíclicos de diaminopiridina como inhibidores de Syk
|
|
WO2013131609A1
(en)
|
2012-03-07 |
2013-09-12 |
Merck Patent Gmbh |
Triazolopyrazine derivatives
|
|
JP6096879B2
(ja)
|
2012-03-28 |
2017-03-15 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ |
二環式ピラジノン誘導体
|
|
WO2013144532A1
(en)
|
2012-03-30 |
2013-10-03 |
Astrazeneca Ab |
3 -cyano- 5 -arylamino-7 -cycloalkylaminopyrrolo [1, 5 -a] pyrimidine derivatives and their use as antitumor agents
|
|
CN104245738B
(zh)
|
2012-04-05 |
2018-02-02 |
弗·哈夫曼-拉罗切有限公司 |
针对人tweak和人il17的双特异性抗体及其用途
|
|
US9676813B2
(en)
|
2012-04-29 |
2017-06-13 |
Neupharma, Inc. |
Certain steroids and methods for using the same in the treatment of cancer
|
|
EA027628B1
(ru)
|
2012-05-04 |
2017-08-31 |
Мерк Патент Гмбх |
Производные пирролотриазинона
|
|
GB201211021D0
(en)
|
2012-06-21 |
2012-08-01 |
Cancer Rec Tech Ltd |
Pharmaceutically active compounds
|
|
AU2013295391B2
(en)
|
2012-07-24 |
2018-03-08 |
Merck Patent Gmbh |
Hydroxystatin derivatives for treatment of arthrosis
|
|
US9725462B2
(en)
|
2012-08-07 |
2017-08-08 |
Merck Patent Gmbh |
Pyridopyrimidine derivatives as protein kinase inhibitors
|
|
CN104507912B
(zh)
|
2012-08-08 |
2016-09-28 |
默克专利股份公司 |
(氮杂-)异喹啉酮衍生物
|
|
WO2014026243A1
(en)
|
2012-08-17 |
2014-02-20 |
Cancer Therapeutics Crc Pty Limited |
Vegfr3 inhibitors
|
|
CN102898330B
(zh)
*
|
2012-09-03 |
2015-02-25 |
浙江大学 |
秋水仙碱衍生物
|
|
WO2014041349A1
(en)
|
2012-09-12 |
2014-03-20 |
Cancer Therapeutics Crc Pty Ltd |
Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors
|
|
US9688635B2
(en)
|
2012-09-24 |
2017-06-27 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
|
CN104662006B
(zh)
|
2012-09-26 |
2017-10-24 |
默克专利股份公司 |
作为parp抑制剂的喹唑酮衍生物
|
|
WO2014063205A1
(en)
|
2012-10-26 |
2014-05-01 |
The University Of Queensland |
Use of endocytosis inhibitors and antibodies for cancer therapy
|
|
EP3354752B1
(en)
|
2012-11-05 |
2020-03-11 |
GMDx Co Pty Ltd |
Methods for determining the cause of somatic mutagenesis
|
|
US9725421B2
(en)
|
2012-11-12 |
2017-08-08 |
Neupharma, Inc. |
Substituted quinoxalines as B-raf kinase inhibitors
|
|
HK1212671A1
(zh)
|
2012-11-16 |
2016-06-17 |
Merck Patent Gmbh |
3-氨基环戊烷甲酰胺衍生物
|
|
US9353150B2
(en)
|
2012-12-04 |
2016-05-31 |
Massachusetts Institute Of Technology |
Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
|
|
EP3381917B1
(en)
|
2013-01-31 |
2021-09-08 |
Bellus Health Cough Inc. |
Imidazopyridine compounds and uses thereof
|
|
WO2014127881A1
(de)
|
2013-02-25 |
2014-08-28 |
Merck Patent Gmbh |
2-amino-3,4-dihydrc-chinazolin derivate und ihre verwendung als cathepsin d inhibitoren
|
|
ES2614872T3
(es)
|
2013-03-05 |
2017-06-02 |
Merck Patent Gmbh |
Derivados de 9-(aril o heteroaril)-2-(pirazolilo, pirrolidinilo o ciclopentilo) aminopurina como agentes anticancer
|
|
WO2014144715A1
(en)
|
2013-03-15 |
2014-09-18 |
Memorial Sloan-Kettering Cancer Center |
Hsp90-targeted cardiac imaging and therapy
|
|
CN105142648A
(zh)
|
2013-03-15 |
2015-12-09 |
玛格塞蒂克斯公司 |
用于癌症的镁组合物及其用途
|
|
AR095443A1
(es)
|
2013-03-15 |
2015-10-14 |
Fundación Centro Nac De Investig Oncológicas Carlos Iii |
Heterociclos condensados con acción sobre atr
|
|
WO2014161570A1
(en)
|
2013-04-03 |
2014-10-09 |
Roche Glycart Ag |
Antibodies against human il17 and uses thereof
|
|
WO2014195507A1
(en)
|
2013-06-07 |
2014-12-11 |
Universite Catholique De Louvain |
3-carboxy substituted coumarin derivatives with a potential utility for the treatment of cancer diseases
|
|
CN105555365A
(zh)
|
2013-06-25 |
2016-05-04 |
堪培拉大学 |
用于调控癌症干细胞的方法和组合物
|
|
NZ718190A
(en)
|
2013-08-23 |
2017-10-27 |
Neupharma Inc |
Substituted quinazolines for inhibiting kinase activity
|
|
US10124001B2
(en)
|
2013-09-18 |
2018-11-13 |
University Of Canberra |
Stem cell modulation II
|
|
US20160298197A1
(en)
|
2013-10-01 |
2016-10-13 |
Queensland University Of Technology |
Kits and methods for diagnosis, screening, treatment and disease monitoring
|
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
|
GB201403536D0
(en)
|
2014-02-28 |
2014-04-16 |
Cancer Rec Tech Ltd |
Inhibitor compounds
|
|
EP3185858A4
(en)
|
2014-08-25 |
2017-12-27 |
University of Canberra |
Compositions for modulating cancer stem cells and uses therefor
|
|
AU2015349613B2
(en)
|
2014-11-17 |
2022-01-13 |
The Council Of The Queensland Institute Of Medical Research |
Glycoprotein biomarkers for esophageal adenocarcinoma and barrett's esophagus and uses thereof
|
|
MA41179A
(fr)
|
2014-12-19 |
2017-10-24 |
Cancer Research Tech Ltd |
Composés inhibiteurs de parg
|
|
GB201501870D0
(en)
|
2015-02-04 |
2015-03-18 |
Cancer Rec Tech Ltd |
Autotaxin inhibitors
|
|
GB201502020D0
(en)
|
2015-02-06 |
2015-03-25 |
Cancer Rec Tech Ltd |
Autotaxin inhibitory compounds
|
|
AU2016220219B2
(en)
|
2015-02-17 |
2020-05-14 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
|
GB201510019D0
(en)
|
2015-06-09 |
2015-07-22 |
Cancer Therapeutics Crc Pty Ltd |
Compounds
|
|
EP3957637B1
(en)
|
2015-08-04 |
2023-06-28 |
Aucentra Therapeutics Pty Ltd |
N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds
|
|
US11225690B2
(en)
|
2015-08-26 |
2022-01-18 |
Gmdx Co Pty Ltd |
Methods of detecting cancer recurrence
|
|
SG10202008046UA
(en)
|
2015-12-23 |
2020-09-29 |
Univ Queensland Technology |
Nucleic acid oligomers and uses therefor
|
|
AU2017214761B2
(en)
|
2016-02-01 |
2024-02-01 |
Epiaxis Therapeutics Pty Ltd |
Proteinaceous compounds and uses therefor
|
|
US20210322415A1
(en)
|
2016-02-15 |
2021-10-21 |
Astrazeneca Ab |
Methods comprising fixed intermittent dosing of cediranib
|
|
ES2925698T3
(es)
|
2016-04-15 |
2022-10-19 |
Cancer Research Tech Ltd |
Compuestos heterocíclicos como inhibidores de la quinasa RET
|
|
GB2554333A
(en)
|
2016-04-26 |
2018-04-04 |
Big Dna Ltd |
Combination therapy
|
|
US10918627B2
(en)
|
2016-05-11 |
2021-02-16 |
Massachusetts Institute Of Technology |
Convergent and enantioselective total synthesis of Communesin analogs
|
|
HUE059242T2
(hu)
|
2016-07-29 |
2022-11-28 |
Rapt Therapeutics Inc |
Azetidin-származékok mint kemokin receptor modulátorok és felhasználásuk
|
|
AU2017312561B2
(en)
|
2016-08-15 |
2022-06-30 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
|
ES2845048T3
(es)
|
2016-09-22 |
2021-07-23 |
Cancer Research Tech Ltd |
Preparación y usos de derivados de pirimidinona
|
|
GB201617103D0
(en)
|
2016-10-07 |
2016-11-23 |
Cancer Research Technology Limited |
Compound
|
|
US10786502B2
(en)
|
2016-12-05 |
2020-09-29 |
Apros Therapeutics, Inc. |
Substituted pyrimidines containing acidic groups as TLR7 modulators
|
|
CN110177780B
(zh)
|
2016-12-05 |
2022-11-01 |
阿普罗斯治疗公司 |
含有酸性基团的嘧啶化合物
|
|
CN110418789B
(zh)
|
2017-02-01 |
2022-03-25 |
常州千红生化制药股份有限公司 |
作为治疗剂的N-环烷基/杂环烷基-4-(咪唑并[1,2-a]吡啶)嘧啶-2-胺的衍生物
|
|
EP3592730B1
(en)
|
2017-03-09 |
2021-08-04 |
Truly Translational Sweden AB |
Prodrugs of sulfasalazine, pharmaceutical compositions thereof and their use in the treatment of autoimmune disease
|
|
GB201704325D0
(en)
|
2017-03-17 |
2017-05-03 |
Argonaut Therapeutics Ltd |
Compounds
|
|
GB201705971D0
(en)
|
2017-04-13 |
2017-05-31 |
Cancer Res Tech Ltd |
Inhibitor compounds
|
|
WO2018209239A1
(en)
|
2017-05-11 |
2018-11-15 |
Massachusetts Institute Of Technology |
Potent agelastatin derivatives as modulators for cancer invasion and metastasis
|
|
CN108864079B
(zh)
|
2017-05-15 |
2021-04-09 |
深圳福沃药业有限公司 |
一种三嗪化合物及其药学上可接受的盐
|
|
ES2975661T3
(es)
|
2017-05-26 |
2024-07-11 |
Cancer Research Tech Ltd |
Inhibidores de BCL6 derivados de la 2-quinolona
|
|
JP7202315B2
(ja)
|
2017-05-26 |
2023-01-11 |
キャンサー・リサーチ・テクノロジー・リミテッド |
ベンズイミダゾロン由来のｂｃｌ６阻害剤
|
|
PL3630188T3
(pl)
|
2017-05-31 |
2022-01-03 |
Amplio Pharma Ab |
Kompozycja farmaceutyczna zawierająca kombinację metotreksatu i nowobiocyny oraz zastosowanie wspomnianej kompozycji w terapii
|
|
US11400160B2
(en)
|
2017-07-05 |
2022-08-02 |
E.P.O.S Iasis Research And Development Limited |
Multifunctional conjugates
|
|
JP7336434B2
(ja)
|
2017-08-01 |
2023-08-31 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
アデノシン受容体アンタゴニストとしてのチアゾロピリジン誘導体
|
|
CN111278840B
(zh)
|
2017-08-18 |
2023-11-17 |
癌症研究科技有限公司 |
吡咯并[2，3-b]吡啶化合物及其治疗癌症的用途
|
|
JP7287952B2
(ja)
|
2017-08-21 |
2023-06-06 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
アデノシン受容体アンタゴニストとしてのベンズイミダゾール誘導体
|
|
ES2964026T3
(es)
|
2017-08-21 |
2024-04-03 |
Merck Patent Gmbh |
Derivados de quinoxalina como antagonistas de receptores de adenosina
|
|
TWI702205B
(zh)
|
2017-10-06 |
2020-08-21 |
俄羅斯聯邦商拜奧卡德聯合股份公司 |
表皮生長因子受體抑制劑
|
|
US10640508B2
(en)
|
2017-10-13 |
2020-05-05 |
Massachusetts Institute Of Technology |
Diazene directed modular synthesis of compounds with quaternary carbon centers
|
|
NL2019801B1
(en)
|
2017-10-25 |
2019-05-02 |
Univ Leiden |
Delivery vectors
|
|
BR112020009055A2
(pt)
|
2017-11-06 |
2020-11-03 |
Rapt Therapeutics, Inc. |
moduladores de receptor de quimiocina para tratamento de câncer positivo para vírus epstein barr
|
|
EP3488868B1
(en)
|
2017-11-23 |
2023-09-13 |
medac Gesellschaft für klinische Spezialpräparate mbH |
Pharmaceutical composition for oral administration containing sulfasalazine and / or a sulfasalazine organic salt, production process and use
|
|
EP3489222A1
(en)
|
2017-11-23 |
2019-05-29 |
medac Gesellschaft für klinische Spezialpräparate mbH |
Sulfasalazine salts, production processes and uses
|
|
US11325900B2
(en)
|
2018-01-15 |
2022-05-10 |
Aucentra Holdings Pty Ltd |
5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents
|
|
GB201801128D0
(en)
|
2018-01-24 |
2018-03-07 |
Univ Oxford Innovation Ltd |
Compounds
|
|
MX2020007812A
(es)
|
2018-01-26 |
2020-11-24 |
Rapt Therapeutics Inc |
Moduladores del receptor de quimiocina y usos de los mismos.
|
|
AU2019218893B2
(en)
|
2018-02-08 |
2024-12-05 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
|
WO2019175093A1
(en)
|
2018-03-12 |
2019-09-19 |
Astrazeneca Ab |
Method for treating lung cancer
|
|
AU2019253510B2
(en)
|
2018-04-13 |
2023-08-10 |
Cancer Research Technology Limited |
BCL6 inhibitors
|
|
BR112020024062A2
(pt)
|
2018-04-27 |
2021-02-09 |
Spruce Biosciences, Inc. |
métodos para o tratamento de tumores de restos adrenais de testículo e de ovário
|
|
GB201809102D0
(en)
|
2018-06-04 |
2018-07-18 |
Univ Oxford Innovation Ltd |
Compounds
|
|
JP7351859B2
(ja)
|
2018-06-04 |
2023-09-27 |
アプロス セラピューティクス， インコーポレイテッド |
Ｔｌｒ７の調節に関係する疾患を処置するのに有用な酸性基を含むピリミジン化合物
|
|
JP2021527051A
(ja)
|
2018-06-05 |
2021-10-11 |
ラプト・セラピューティクス・インコーポレイテッド |
ピラゾロ−ピリミジン−アミノ−シクロアルキル化合物及びその治療的使用
|
|
GB201810092D0
(en)
|
2018-06-20 |
2018-08-08 |
Ctxt Pty Ltd |
Compounds
|
|
GB201810581D0
(en)
|
2018-06-28 |
2018-08-15 |
Ctxt Pty Ltd |
Compounds
|
|
RS66314B1
(sr)
|
2018-09-18 |
2025-01-31 |
Hoffmann La Roche |
Derivati hinazolina kao antitumorski agensi
|
|
WO2020068600A1
(en)
|
2018-09-24 |
2020-04-02 |
Rapt Therapeutics, Inc. |
Ubiquitin-specific-processing protease 7 (usp7) modulators and uses thereof
|
|
CA3117512A1
(en)
|
2018-10-25 |
2020-04-30 |
Merck Patent Gmbh |
5-azaindazole derivatives as adenosine receptor antagonists
|
|
EP3870582B1
(en)
|
2018-10-25 |
2023-07-19 |
Merck Patent GmbH |
5-azaindazole derivatives as adenosine receptor antagonists
|
|
GB201819126D0
(en)
|
2018-11-23 |
2019-01-09 |
Cancer Research Tech Ltd |
Inhibitor compounds
|
|
US20230272402A1
(en)
|
2018-12-25 |
2023-08-31 |
Institute Of Basic Medical Sciences Chinese Academy Of Medical Sciences |
Small rna medicament for prevention and treatment of inflammation-related diseases and combination thereof
|
|
AR117844A1
(es)
|
2019-01-22 |
2021-09-01 |
Merck Patent Gmbh |
Derivados de tiazolopiridina como antagonistas del receptor de adenosina
|
|
AU2020228760A1
(en)
|
2019-02-25 |
2021-09-23 |
Glaxosmithkline Intellectual Property (No. 3) Limited |
Treatment with P2X3 modulators
|
|
JP7734586B2
(ja)
|
2019-03-07 |
2025-09-05 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｓｈｐ２アンタゴニストとしてのカルボキサミド－ピリミジン誘導体
|
|
JP7523465B2
(ja)
|
2019-03-28 |
2024-07-26 |
アンプリア セラピューティクス リミテッド |
Ｆａｋ阻害剤の塩及び結晶形態
|
|
CN111747950B
(zh)
|
2019-03-29 |
2024-01-23 |
深圳福沃药业有限公司 |
用于治疗癌症的嘧啶衍生物
|
|
US12465608B2
(en)
|
2019-03-29 |
2025-11-11 |
Astrazeneca Ab |
Osimertinib for use in the treatment of non-small cell lung cancer
|
|
WO2020201773A1
(en)
|
2019-04-05 |
2020-10-08 |
Storm Therapeutics Ltd |
Mettl3 inhibitory compounds
|
|
CA3127475A1
(en)
|
2019-04-08 |
2020-10-15 |
Merck Patent Gmbh |
Pyrimidinone derivatives as shp2 antagonists
|
|
GB201905328D0
(en)
|
2019-04-15 |
2019-05-29 |
Azeria Therapeutics Ltd |
Inhibitor compounds
|
|
WO2020247054A1
(en)
|
2019-06-05 |
2020-12-10 |
Massachusetts Institute Of Technology |
Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
|
|
GB201908885D0
(en)
|
2019-06-20 |
2019-08-07 |
Storm Therapeutics Ltd |
Therapeutic compounds
|
|
US20220298143A1
(en)
|
2019-08-31 |
2022-09-22 |
Etern Biopharma (Shanghai) Co., Ltd. |
Pyrazole Derivatives for FGFR Inhibitor and Preparation Method Thereof
|
|
TWI873187B
(zh)
|
2019-09-20 |
2025-02-21 |
美商愛德亞生物科學公司 |
作為parg抑制劑之4-取代的吲哚及吲唑磺醯胺衍生物
|
|
GB201913988D0
(en)
|
2019-09-27 |
2019-11-13 |
Celleron Therapeutics Ltd |
Novel treatment
|
|
GB201914860D0
(en)
|
2019-10-14 |
2019-11-27 |
Cancer Research Tech Ltd |
Inhibitor compounds
|
|
GB201915831D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
|
GB201915829D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
|
GB201915828D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
|
US12195458B2
(en)
|
2019-12-02 |
2025-01-14 |
Storm Therapeutics Limited |
Polyheterocyclic compounds as METTL3 inhibitors
|
|
GB202004960D0
(en)
|
2020-04-03 |
2020-05-20 |
Kinsenus Ltd |
Inhibitor compounds
|
|
GB202008201D0
(en)
|
2020-06-01 |
2020-07-15 |
Neophore Ltd |
Inhibitor compounds
|
|
GB202012482D0
(en)
|
2020-08-11 |
2020-09-23 |
Univ Of Huddersfield |
Novel compounds and therapeutic uses thereof
|
|
GB202012969D0
(en)
|
2020-08-19 |
2020-09-30 |
Univ Of Oxford |
Inhibitor compounds
|
|
WO2022074379A1
(en)
|
2020-10-06 |
2022-04-14 |
Storm Therapeutics Limited |
Mettl3 inhibitory compounds
|
|
US20240101589A1
(en)
|
2020-10-08 |
2024-03-28 |
Strom Therapeutics Limited |
Inhibitors of mettl3
|
|
WO2022182415A1
(en)
|
2021-02-24 |
2022-09-01 |
Massachusetts Institute Of Technology |
Himastatin derivatives, and processes of preparation thereof, and uses thereof
|
|
GB202102895D0
(en)
|
2021-03-01 |
2021-04-14 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
|
WO2022197641A1
(en)
|
2021-03-15 |
2022-09-22 |
Rapt Therapeutics, Inc. |
1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases
|
|
US20250281633A1
(en)
|
2021-05-03 |
2025-09-11 |
Merck Patent Gmbh |
Her2 targeting fc antigen binding fragment-drug conjugates
|
|
TW202306568A
(zh)
|
2021-05-17 |
2023-02-16 |
南韓商怡諾安有限公司 |
苯甲醯胺衍生物、包含其之醫藥組成物、包含其之健康功能食品組成物、包含其之組合製劑、及其用途
|
|
CN117999101A
(zh)
|
2021-05-25 |
2024-05-07 |
默克专利股份公司 |
靶向EGFR的Fc抗原结合片段-药物缀合物
|
|
GB202107907D0
(en)
|
2021-06-02 |
2021-07-14 |
Storm Therapeutics Ltd |
Combination therapies
|
|
GB202108383D0
(en)
|
2021-06-11 |
2021-07-28 |
Argonaut Therapeutics Ltd |
Compounds useful in the treatment or prevention of a prmt5-mediated disorder
|
|
GB202110373D0
(en)
|
2021-07-19 |
2021-09-01 |
Neophore Ltd |
Inhibitor compounds
|
|
IT202100023357A1
(it)
|
2021-09-09 |
2023-03-09 |
Cheirontech S R L |
Peptidi con attività anti-angiogenica
|
|
CA3225500A1
(en)
|
2021-10-04 |
2023-04-13 |
Ulrich Luecking |
Parg inhibitory compounds
|
|
WO2023057394A1
(en)
|
2021-10-04 |
2023-04-13 |
Forx Therapeutics Ag |
N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
|
|
GB202117224D0
(en)
|
2021-11-29 |
2022-01-12 |
Neophore Ltd |
Inhibitor compounds
|
|
GB202117225D0
(en)
|
2021-11-29 |
2022-01-12 |
Neophore Ltd |
Protac compounds
|
|
US20250084074A1
(en)
|
2022-01-10 |
2025-03-13 |
Merck Patent Gmbh |
Substituted heterocycles as hset inhibitors
|
|
GB202202006D0
(en)
|
2022-02-15 |
2022-03-30 |
Chancellor Masters And Scholars Of The Univ Of Oxford |
Anti-cancer treatment
|
|
GB202202199D0
(en)
|
2022-02-18 |
2022-04-06 |
Cancer Research Tech Ltd |
Compounds
|
|
WO2023175185A1
(en)
|
2022-03-17 |
2023-09-21 |
Forx Therapeutics Ag |
2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
|
|
WO2023175184A1
(en)
|
2022-03-17 |
2023-09-21 |
Forx Therapeutics Ag |
2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
|
|
GB202204935D0
(en)
|
2022-04-04 |
2022-05-18 |
Cambridge Entpr Ltd |
Nanoparticles
|
|
AU2023248361A1
(en)
|
2022-04-06 |
2024-10-10 |
Rapt Therapeutics, Inc. |
Chemokine receptor modulators and uses thereof
|
|
AU2023268009A1
(en)
|
2022-05-11 |
2024-12-19 |
Cancer Research Technology Limited |
Ikk inhibitors
|
|
GB202209404D0
(en)
|
2022-06-27 |
2022-08-10 |
Univ Of Sussex |
Compounds
|
|
EP4565592A1
(en)
|
2022-08-01 |
2025-06-11 |
Neupharma, Inc. |
Crystalline salts of crystalline salts of (3s,5r,8r,9s,10s,13r,14s,17r)-14-hydroxy-10,13-dimethyl-17-(2- oxo-2h-pyran-5-yl)hexadecahydro-1h-cyclopenta[a]phenanthren-3-yl piperazine-1-carboxylate
|
|
GB202213166D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
|
GB202213163D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
|
GB202213167D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
|
GB202213162D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Prodrugs
|
|
GB202213164D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
|
AU2023355735A1
(en)
|
2022-10-03 |
2025-04-03 |
Forx Therapeutics Ag |
Parg inhibitory compound
|
|
WO2024094963A1
(en)
|
2022-11-02 |
2024-05-10 |
Cancer Research Technology Limited |
2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one and 7-amino-1-pyrimido[4,5-d]pyrimidin-2(1 h)-one derivatives as egfr inhibitors for the treatment of cancer
|
|
EP4612149A1
(en)
|
2022-11-02 |
2025-09-10 |
Cancer Research Technology Limited |
Pyrido[2,3-d]pyrimidin-2-amine derivatives as egfr inhibitors for the treatment of cancer
|
|
AU2023375996A1
(en)
|
2022-11-07 |
2025-06-19 |
Merck Patent Gmbh |
Substituted bi-and tricyclic hset inhibitors
|
|
GB202218672D0
(en)
|
2022-12-12 |
2023-01-25 |
Storm Therapeutics Ltd |
Inhibitory compounds
|
|
GB202300881D0
(en)
|
2023-01-20 |
2023-03-08 |
Neophore Ltd |
Inhibitor compounds
|
|
WO2024173514A1
(en)
|
2023-02-14 |
2024-08-22 |
Ideaya Biosciences, Inc. |
Amide and ester-substituted imidazopyridine compounds
|
|
WO2024173453A1
(en)
|
2023-02-14 |
2024-08-22 |
Ideaya Biosciences, Inc. |
Heteroaryl-substituted imidazopyridine compounds
|
|
WO2024173524A1
(en)
|
2023-02-14 |
2024-08-22 |
Ideaya Biosciences, Inc. |
Heteroaryl-substituted benzimidazole compounds
|
|
WO2024173530A1
(en)
|
2023-02-14 |
2024-08-22 |
Ideaya Biosciences, Inc. |
Heteroaryl-substituted pyrazolo/imidazo pyridine compounds
|
|
US12145945B2
(en)
|
2023-03-10 |
2024-11-19 |
Breakpoint Therapeutics Gmbh |
Compounds, compositions, and therapeutic uses thereof
|
|
WO2024209035A1
(en)
|
2023-04-05 |
2024-10-10 |
Forx Therapeutics Ag |
Parg inhibitory compounds
|
|
GB202306601D0
(en)
|
2023-05-04 |
2023-06-21 |
Cancer Research Tech Ltd |
Inhibitor compounds
|
|
GB202307924D0
(en)
|
2023-05-26 |
2023-07-12 |
Neophore Ltd |
Inhibitor compounds
|
|
GB2631507A
(en)
|
2023-07-04 |
2025-01-08 |
Univ Liverpool |
Compositions
|
|
GB2631509A
(en)
|
2023-07-04 |
2025-01-08 |
Univ Liverpool |
Compositions
|
|
WO2025046148A1
(en)
|
2023-09-01 |
2025-03-06 |
Forx Therapeutics Ag |
Novel parg inhibitors
|
|
WO2025056923A1
(en)
|
2023-09-15 |
2025-03-20 |
Cambridge Enterprise Limited |
Combination therapy
|
|
WO2025073792A1
(en)
|
2023-10-02 |
2025-04-10 |
Forx Therapeutics Ag |
Wrn inhibitory compounds
|
|
GB202315149D0
(en)
|
2023-10-03 |
2023-11-15 |
Celleron Therapeutics Ltd |
Combination therapy
|
|
WO2025073870A1
(en)
|
2023-10-03 |
2025-04-10 |
Forx Therapeutics Ag |
Parg inhibitory compound
|
|
GB202316595D0
(en)
|
2023-10-30 |
2023-12-13 |
Storm Therapeutics Ltd |
Inhibitory compounds
|
|
GB202316683D0
(en)
|
2023-10-31 |
2023-12-13 |
Storm Therapeutics Ltd |
Inhibitory compounds
|
|
WO2025093755A1
(en)
|
2023-11-01 |
2025-05-08 |
Forx Therapeutics Ag |
Novel parc inhibitors
|
|
GB202317368D0
(en)
|
2023-11-13 |
2023-12-27 |
Breakpoint Therapeutics Gmbh |
Novel compounds, compositions and therapeutic uses thereof
|
|
WO2025104443A1
(en)
|
2023-11-14 |
2025-05-22 |
Storm Therapeutics Ltd |
Inhibitory compounds
|
|
WO2025114480A1
(en)
|
2023-11-28 |
2025-06-05 |
Forx Therapeutics Ag |
Wrn inhibitory compounds
|
|
WO2025136811A1
(en)
|
2023-12-18 |
2025-06-26 |
Ideaya Biosciences, Inc. |
Chemical compounds and uses thereof
|
|
GB202319864D0
(en)
|
2023-12-21 |
2024-02-07 |
Breakpoint Therapeutics Gmbh |
Novel compounds, compositions and therapeutic uses thereof
|
|
GB202319863D0
(en)
|
2023-12-21 |
2024-02-07 |
Breakpoint Therapeutics Gmbh |
Movel compounds, compositions and therapeutics uses thereof
|
|
WO2025133395A1
(en)
|
2023-12-22 |
2025-06-26 |
Forx Therapeutics Ag |
Bicyclic (hetero)arylene wrn inhibitory compounds
|
|
WO2025133396A1
(en)
|
2023-12-22 |
2025-06-26 |
Forx Therapeutics Ag |
Novel bicyclo heteroaryl parg inhibitors
|
|
WO2025191176A1
(en)
|
2024-03-14 |
2025-09-18 |
Forx Therapeutics Ag |
Wrn inhibitory compounds
|
|
WO2025194036A1
(en)
*
|
2024-03-14 |
2025-09-18 |
Washington University |
Autophagy enhancers
|
|
NL2037411B1
(en)
|
2024-04-08 |
2025-10-31 |
Univ Leiden |
Protac compounds
|
|
GB202407738D0
(en)
|
2024-05-31 |
2024-07-17 |
Storm Therapeutics Ltd |
Inhibitory compounds
|
|
WO2025262192A1
(en)
|
2024-06-21 |
2025-12-26 |
Breakpoint Therapeutics Gmbh |
Quinazoline derivatives suitable for use as werner syndrome helicase protein inhibitors
|
|
WO2026003380A1
(en)
|
2024-06-28 |
2026-01-02 |
Forx Therapeutics Ag |
Wrn inhibitory compounds
|
|
WO2026022150A1
(en)
|
2024-07-22 |
2026-01-29 |
Forx Therapeutics Ag |
Parg inhibitory compounds
|